Literature DB >> 22447111

Serum osteocalcin levels are useful as a predictor of cardiovascular events in maintenance hemodialysis patients.

Tetsuri Yamashita1, Kazuhiro Okano, Yuki Tsuruta, Takashi Akiba, Kosaku Nitta.   

Abstract

BACKGROUNDS: Osteocalcin (OC) is a known bone metabolic marker and a regulator of glucose and fat metabolisms. Although bone and energy metabolisms are known risk factors for cardiovascular disease (CVD) in hemodialysis (HD) patients, few studies have examined the correlation between OC and CVD. The purpose of this study was to investigate the impact of serum OC levels on the emergence of new CVD events in HD patients.
METHODS: We designed a longitudinal, observational cohort study in which the study patients were divided into low- and high-serum OC groups based on a median serum OC level of 71.5 ng/ml.
RESULTS: Cardiovascular disease events were observed in 29 of 126 patients (23.0 %). The number of cumulative CVD events in the low-serum OC group was significantly higher than that in the high-serum OC group, as evaluated by the Kaplan-Meier method (p = 0.0021, log-rank test). Multivariate Cox proportional hazards analysis demonstrated that a low level of serum OC is a significant predictor of a higher incidence of CVD events [hazard ratio, 2.925; 95 % confidence interval, 1.048-9.066; p = 0.0401] after adjustment.
CONCLUSION: Serum OC level is a significant, independent prognostic factor for CVD events in maintenance HD patients. OC may be useful in predicting new CVD events in HD patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22447111     DOI: 10.1007/s11255-012-0156-6

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  28 in total

1.  High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death.

Authors:  Margaret J Blayney; Ronald L Pisoni; Jennifer L Bragg-Gresham; Juergen Bommer; Luis Piera; Akira Saito; Takashi Akiba; Marcia L Keen; Eric W Young; Friedrich K Port
Journal:  Kidney Int       Date:  2008-06-11       Impact factor: 10.612

2.  Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease.

Authors:  Carmine Zoccali; Francesca Mallamaci; Giovanni Tripepi; Francesco A Benedetto; Sebastiano Cutrupi; Saverio Parlongo; Lorenzo S Malatino; Graziella Bonanno; Giuseppe Seminara; Francesco Rapisarda; Pasquale Fatuzzo; Michele Buemi; Giacomo Nicocia; Sachiyo Tanaka; Noriyuki Ouchi; Shinji Kihara; Tohru Funahashi; Yuji Matsuzawa
Journal:  J Am Soc Nephrol       Date:  2002-01       Impact factor: 10.121

3.  A new assay method that detects only intact osteocalcin. Two-step non-invasive diagnosis to predict adynamic bone disease in haemodialysed patients.

Authors:  T Morishita; M Nomura; M Hanaoka; T Saruta; T Matsuo; Y Tsukamoto
Journal:  Nephrol Dial Transplant       Date:  2000-05       Impact factor: 5.992

4.  Origin of the vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone.

Authors:  P A Price; M K Williamson; J W Lothringer
Journal:  J Biol Chem       Date:  1981-12-25       Impact factor: 5.157

5.  Associations of total osteocalcin with all-cause and cardiovascular mortality in older men. The Health In Men Study.

Authors:  B B Yeap; S A P Chubb; L Flicker; K A McCaul; P R Ebeling; G J Hankey; J P Beilby; P E Norman
Journal:  Osteoporos Int       Date:  2011-02-26       Impact factor: 4.507

Review 6.  Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure.

Authors:  S G Rostand; T B Drüeke
Journal:  Kidney Int       Date:  1999-08       Impact factor: 10.612

Review 7.  Energy regulation by the skeleton.

Authors:  George Wolf
Journal:  Nutr Rev       Date:  2008-04       Impact factor: 7.110

8.  Endocrine regulation of energy metabolism by the skeleton.

Authors:  Na Kyung Lee; Hideaki Sowa; Eiichi Hinoi; Mathieu Ferron; Jong Deok Ahn; Cyrille Confavreux; Romain Dacquin; Patrick J Mee; Marc D McKee; Dae Young Jung; Zhiyou Zhang; Jason K Kim; Franck Mauvais-Jarvis; Patricia Ducy; Gerard Karsenty
Journal:  Cell       Date:  2007-08-10       Impact factor: 41.582

9.  Serum and dialysate osteocalcin levels in hemodialysis and peritoneal dialysis patients and after renal transplantation.

Authors:  S Epstein; H Traberg; R Raja; J Poser
Journal:  J Clin Endocrinol Metab       Date:  1985-06       Impact factor: 5.958

10.  FoxO1 expression in osteoblasts regulates glucose homeostasis through regulation of osteocalcin in mice.

Authors:  Marie-Therese Rached; Aruna Kode; Barbara C Silva; Dae Young Jung; Susan Gray; Helena Ong; Ji-Hye Paik; Ronald A DePinho; Jason K Kim; Gerard Karsenty; Stavroula Kousteni
Journal:  J Clin Invest       Date:  2009-12-14       Impact factor: 14.808

View more
  5 in total

Review 1.  An overview of osteocalcin progress.

Authors:  Jinqiao Li; Hongyu Zhang; Chao Yang; Yinghui Li; Zhongquan Dai
Journal:  J Bone Miner Metab       Date:  2016-01-08       Impact factor: 2.626

Review 2.  Multifaceted interaction of bone, muscle, lifestyle interventions and metabolic and cardiovascular disease: role of osteocalcin.

Authors:  I Levinger; T C Brennan-Speranza; A Zulli; L Parker; X Lin; J R Lewis; B B Yeap
Journal:  Osteoporos Int       Date:  2017-03-13       Impact factor: 4.507

3.  Low serum osteocalcin levels are correlated with left ventricular systolic dysfunction and cardiac death in Chinese men.

Authors:  Xue-Li Zhang; Yun Shen; Xiao-Jing Ma; Zhi-Gang Lu; Yi-Ting Xu; Qin Xiong; Yu-Qian Bao
Journal:  Acta Pharmacol Sin       Date:  2018-07-10       Impact factor: 6.150

4.  Diagnostic performance of bone metabolic indexes for the detection of stroke.

Authors:  Li Ming Tan; Lu Wang; Juan-Juan Chen; Hua Li; Wen-Bo Luo
Journal:  Saudi Med J       Date:  2017-01       Impact factor: 1.484

5.  Endocrine actions of osteocalcin.

Authors:  Aurora Patti; Luigi Gennari; Daniela Merlotti; Francesco Dotta; Ranuccio Nuti
Journal:  Int J Endocrinol       Date:  2013-04-30       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.